Biotech Startups

UniFAHS develops bacteriophage-based products and services to control bacterial contamination and antimicrobial resistance across the food supply chain, serving the poultry, dairy, aquaculture, feed, and food processing sectors. It maintains a phage collection targeting pathogens such as Salmonella, E. coli, Listeria, and Vibrio, and offers a customized phage platform including phage banking, contract research and manufacturing, lab services, and phage-based detection tests.

1 investor

Unima makes portable diagnostic tests that deliver disease identification at the point of care within 15 minutes at low cost, enabling rapid detection and monitoring of infectious diseases.

1 investor

United BioSource connects specialty therapies to patients through evidence development, drug safety management, and patient access solutions for biopharma companies. The company modernizes therapy approval and commercialization pathways by integrating real-world evidence, risk management, and patient journey expertise.

1 investor

UBC provides biopharma companies with services in real-world evidence development, drug safety and risk management (including REMS), and patient access, affordability, and adherence support. Its work focuses on specialty therapies, helping sponsors demonstrate long-term product value and improve patient outcomes.

1 investor

Universal DX develops blood-based tests for early cancer detection, with a focus on colorectal cancer screening. The company runs clinical studies through a network of hospitals and gastrointestinal clinical teams across the U.S. and Europe.

1 investor

Unixell Biotech develops advanced cell therapy platforms including reprogramming, stem cell differentiation, lineage tracing, and gene editing technologies to create neural cell therapeutics for clinical applications. The company's lead program is UX-DA001, a midbrain dopamine precursor cell therapy for Parkinson's disease, which has received clinical trial approval from Chinese and US regulatory authorities.

1 investor

Unobio is a biotech company running drug discovery programs that begin with patient data and validate candidates against patient biology at each stage, aiming to improve translation rates from preclinical work to clinical trials. Its approach targets the failure of programs that clear in vitro and animal models but fail in later-stage clinical phases.

1 investor

Unravel Bio uses computational drug discovery and advanced animal models to accelerate pharmaceutical development with lower cost and risk. The company serves biopharma partners, foundations, and patients seeking treatments for rare and complex diseases.

1 investor

Unveil Instruments develops LightWeigh, a compact interferometric microscope for characterizing nanoparticles (20-300nm) including AAVs, lentiviruses, LNPs, and extracellular vesicles at single-particle level, serving gene therapy and biotech production teams.

1 investor

Institute of Organic Chemistry and Biochemistry (IOCB) is a research institution under the Czech Academy of Sciences conducting basic research at the intersection of chemistry, biology, and computational sciences, with a systematic infrastructure for translating scientific discoveries into commercial products and technologies.

1 investor

1 investor

Uquifa is a supplier of active pharmaceutical ingredients and related products for the human and animal health markets, emphasizing quality standards and regulatory compliance. The company organizes its business around what it calls its "3P's": People, Products, and Plants.

1 investor

Urania Therapeutics develops treatments for genetic diseases and cancers caused by nonsense mutations, targeting monogenic diseases in which a single gene defect impairs production of a functional protein. It focuses on rare diseases that collectively affect a large patient population but currently lack curative therapies.

1 investor

UroMems designs and commercializes active implantable medical devices for urology, using proprietary microelectromechanical systems technology. The company serves urology patients and focuses on unmet clinical needs that affect quality of life.

1 investor

US BIOLOGIC develops orally delivered vaccines for disease prevention, applying partner technologies to its oral-delivery platform for wildlife, companion animals, food animals, and humans. The company handles funding, regulatory support, manufacturing, and distribution to commercialize these preventative products.

1 investor

USDTL provides forensic toxicology testing and drug and alcohol testing services. The company serves clients requiring laboratory analysis and test collection.

1 investor

Uute Scientific is a microbiome science company, spun out of research at the University of Helsinki and Tampere University, that develops a nature-derived microbial ingredient intended to reduce the risk of immune-mediated and autoimmune diseases. It supplies this ingredient to companies seeking to add microbial-diversity health benefits to their products.

1 investor

V-Ensure is a pharmaceutical company providing contract research, API development, and cGMP contract manufacturing services. It offers formulation and API R&D, analytical services, and produces injectable, solid oral, and liquid oral products.

1 investor

Vactech develops preventive vaccines and diagnostic technologies for type 1 diabetes, celiac disease, and enterovirus-related conditions. The company combines academic research with clinical development, advancing a patented preventive vaccine for type 1 diabetes through clinical trials with projected commercial impact in the US and EU.

1 investor

Vafseo (vadadustat) is a once-daily oral prescription medicine that treats anemia caused by chronic kidney disease in adults who have been on dialysis for at least three months. It works by increasing erythropoietin to help the body produce more red blood cells, and is marketed by Akebia Therapeutics.

1 investor

Vail Scientific develops VSNO, a non-invasive, point-of-care diagnostic tool for rapid screening of patients suspected of having sepsis to aid in triage. The company serves healthcare providers with medical technology aimed at earlier sepsis diagnosis.

1 investor

VALANX Biotech develops a site-specific protein conjugation technology (GoldenSite) using click-chemistry to produce homogeneous antibody-drug conjugates with optimized conjugation sites. It targets biopharma developers building next-generation ADCs, aiming to widen therapeutic windows and reduce off-target toxicity.

1 investor

Valbiotis develops patented, clinically-tested dietary supplements focused on cardiometabolic health and everyday wellness concerns such as sleep, fatigue, immunity, mood, and vitality. Its plant-based formulas, backed by over a decade of research, are designed for health professionals and consumers and are made in France.

1 investor

Valen designs drugs using computational biology and experimental data generation. The company serves pharmaceutical and biotech researchers developing the next generation of therapeutics.

1 investor